Disc Medicine draws $30M in debt, expands Hercules credit line
What's the deal? Disc Medicine has amended its loan agreement with Hercules CapitalDealroom has a profile for this one. Try Dealroom →, immediately drawing $30 million in post-IPO debt.
The amendment also extends access to several additional $25 million tranches and other advances through mid-2028.
As part of the deal, minimum cash covenant testing has been pushed back to begin on July 1, 2028, easing near-term balance sheet pressure.
Why now? The clinical-stage biotech faces pivotal catalysts, including the APOLLO Phase 3 readout for bitopertin in Q4 2026.
The expanded credit line lets Disc stay on offense around these data readouts without immediately tapping equity markets. That matters for a company with zero revenue and rising losses.
What could go wrong? More debt means more leverage — and it does nothing to remove the core risks around approval timing, trial outcomes, and commercial uptake.
Should key trials disappoint, the added borrowing could weigh on an already cash-burning balance sheet.
The signal: Hercules Capital, an investment fund specialising in venture debt for growth-stage companies, is a natural fit for a late-stage hematology player like Disc Medicine that wants runway without dilution. The amended facility reflects a broader pattern of clinical-stage biotechs leaning on structured debt to bridge to binary readouts — here, the APOLLO Phase 3 data due in Q4 2026.
Read more: Simply Wall St
Image credit: News21 - National
